EHA 2025 | The efficacy and convenience of an all-oral regimen of decitabine and venetoclax in AML

This is an exciting EHA meeting for treatment of AML. I think the abstract that is of a lot of interest to me is the all-oral regimen of oral decitabine and venetoclax that is being presented as an oral presentation. It is interesting because this is a confirmation of a study that we did at our institution and was published in Lancet Hematology, showing that the combination of oral decitabine and venetoclax is effective and convenient, and their activity and response appears to be very similar to the already approved FDA regimen of hypomethylating agents plus venetoclax, which is now very well established for treatment of older and unfit patients with AML. So I think this is an important step for this specific population. These are generally unfit or older patients and having an oral strategy, completely oral strategy, is very convenient for them rather than having to come into a treatment center for five or seven days each month to get their parenteral hypomethylating agent. Again, as I mentioned, we did this trial a couple of years ago, and we were very excited to see that the data, in terms of response rates, are very similar, again, confirming that this is a very feasible strategy.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.